Literature DB >> 14629841

Enteric disposition and recycling of flavonoids and ginkgo flavonoids.

Yong Liu1, Yan Liu, Yang Dai, Luying Xun, Ming Hu.   

Abstract

OBJECTIVE: The objective of this study was to determine the intestinal and microbial disposition of flavonoids and how these disposition processes affect their enteric recycling.
DESIGN: Studies were performed using a perfused rat intestinal model or using enrichment cultures and a pure isolate of Enterococcus avium (LY1).
RESULTS: In the rat intestine, aglycones, such as quercetin and apigenin, were as permeable (P*(eff) > or = 2) as compounds such as propranolol (100% absorption). However, a significant portion of the absorbed aglycones was conjugated and the metabolites were excreted into the lumen. Flavonoid glycosides, such as isoquercitrin and apigenin-7-O-glucoside, also had high apparent P*(eff) values (> or = 2) in the upper small intestine because of rapid hydrolysis. However, isoquercitrin was absorbed much slower (P*(eff) < or = 0.7, p < 0.05) when hydrolysis was absent or inhibited by 20 mmol gluconolactone. Absorption of other intact glycosides was similar to intact isoquercitrin and was much slower than the corresponding aglycones (P*(eff) < or = 0.7, p < 0.05). Intestinal bacteria, such as LY1, hydrolyzed the flavonoid glycosides used in the study. Excreted glycosidases were involved in the hydrolysis of glycosides because glycosides were poorly taken up by LY1. In conclusion, glycosidase-catalyzed hydrolysis is a critical first step in the intestinal and microbial disposition of flavonoid glycosides. Aglycones were not only rapidly absorbed, but also rapidly metabolized into phase II conjugates, which were then excreted back into the lumen. Therefore, intestinal and microbial glycosidases and intestinal phase II enzymes make a significant contribution to the disposition of flavonoids via the proposed enteric and enterohepatic recycling scheme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14629841     DOI: 10.1089/107555303322524481

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  21 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes.

Authors:  Lan Tang; Ling Ye; Rashim Singh; Baojian Wu; Chang Lv; Jie Zhao; Zhongqiu Liu; Ming Hu
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

Review 3.  Commentary: bioavailability of flavonoids and polyphenols: call to arms.

Authors:  Ming Hu
Journal:  Mol Pharm       Date:  2007 Nov-Dec       Impact factor: 4.939

4.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

5.  A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut.

Authors:  Bijun Xia; Qiong Zhou; Zhijie Zheng; Ling Ye; Ming Hu; Zhongqiu Liu
Journal:  Mol Pharm       Date:  2012-10-24       Impact factor: 4.939

6.  Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids.

Authors:  Peimin Dai; Lijun Zhu; Feifei Luo; Linlin Lu; Qiang Li; Liping Wang; Ying Wang; Xinchun Wang; Ming Hu; Zhongqiu Liu
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

7.  Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo).

Authors:  Yan Chen; Yan Hong Zhao; Xiao Bin Jia; Ming Hu
Journal:  Pharm Res       Date:  2008-05-06       Impact factor: 4.200

8.  Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.

Authors:  Olanrewaju Okusanya; Alan Forrest; Robin DiFrancesco; Sanela Bilic; Susan Rosenkranz; Michael F Para; Elizabeth Adams; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts.

Authors:  Yong-Mei Li; Xiao-Mian Li; Guang-Ming Li; Wen-Cai Du; Jing Zhang; Wei-Xia Li; Jianshe Xu; Ming Hu; Ze Zhu
Journal:  J Agric Food Chem       Date:  2008-06-21       Impact factor: 5.279

10.  Constitutional flavonoids derived from Epimedium dose-dependently reduce incidence of steroid-associated osteonecrosis not via direct action by themselves on potential cellular targets.

Authors:  Ge Zhang; Xin-Luan Wang; Hui Sheng; Xin-Hui Xie; Yi-Xin He; Xin-Sheng Yao; Zi-Rong Li; Kwong-Man Lee; Wei He; Kwok-Sui Leung; Ling Qin
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.